Citadel Advisors
SABSW icon

Citadel Advisors’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Citadel Advisors’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,905
Closed -$1K – 15381
2022
Q3 		$1K Buy
19,905
+1,194
+6% +$142 ﹤0.01% 12442
2022
Q2 		$3K Sell
18,711
-776
-4% -$177 ﹤0.01% 12709
2022
Q1 		$9K Sell
19,487
-141
-0.7% -$119 ﹤0.01% 13389
2021
Q4 		$35K Buy
19,628
+753
+4% +$1.38K ﹤0.01% 13415
2021
Q3 		$17K Hold
18,875
– – ﹤0.01% 13657
2021
Q2 		$17K Sell
18,875
-80
-0.4% -$58 ﹤0.01% 13548
2021
Q1 		$11K Buy
+18,955
New +$19.7K ﹤0.01% 13088

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Citadel Advisors's SABSW Position: Q4 2022 in Review

Citadel Advisors sold out of SAB Biotherapeutics Warrant (SABSW) in Q4 2022, closing a stake of 19,905 shares — an estimated $1K sold.

Citadel Advisors first reported a position in SABSW in Q1 2021 and held it in 7 quarters. The position peaked at $35K in Q4 2021. 13 funds tracked by Wall St. Rank hold SABSW as of Q4 2022.

  • Citadel Advisors reported no remaining SAB Biotherapeutics Warrant position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 19,905 SAB Biotherapeutics Warrant shares in Q4 2022, an estimated $1K.
  • Citadel Advisors first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and held it in 7 quarters.
  • Citadel Advisors's SAB Biotherapeutics Warrant position peaked at $35K in Q4 2021.
  • 13 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.